The abstract is read at the publisher; the summary is JClub's.
rs2129019 in SLC2A2 (GLUT2) is linked to a 38% increased risk of metabolic failure per A allele on glimepiride in African/African American participants.
- Why it matters: Second-line type 2 diabetes treatment shows large person-to-person variability, and current selection does not use genetic information to predict glycemic response.
- What they did: In the GRADE randomized comparative effectiveness trial, a GWAS tested time to HbA1c ≥7% and HbA1c >7.5% failure on add-on therapies, then replicated top variants near SLC2A2 and assessed function via OGTT and an acute glipizide challenge.
- The result: Carriers showed impaired β-cell function and reduced glucose-lowering after sulfonylurea challenge, and zebrafish with slc2a2 disruption confirmed attenuated glimepiride effects.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.